Ascorbic Acid Ameliorates Molecular and Developmental Defects in Human-Induced Pluripotent Stem Cell and Cerebral Organoid Models of Fragile X Syndrome

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Dec 17

PMID 39684429

Authors

Keith M Gunapala

Aseel Gadban

Faiza Noreen

Primo Schar

Nissim Benvenisty

Verdon Taylor

Affiliations

Soon will be listed here.

Abstract

Fragile X Syndrome (FX) is the most common form of inherited cognitive impairment and falls under the broader category of Autism Spectrum Disorders (ASD). FX is caused by a CGG trinucleotide repeat expansion in the non-coding region of the X-linked () gene, leading to its hypermethylation and epigenetic silencing. Animal models of FX rely on the deletion of the gene, which fails to replicate the epigenetic silencing mechanism of the gene observed in human patients. Human stem cells carrying FX repeat expansions have provided a better understanding of the basis of epigenetic silencing of . Previous studies have found that 5-Azacytidine (5Azac) can reverse this methylation; however, 5Azac can be toxic, which may limit its therapeutic potential. Here, we show that the dietary factor Ascorbic Acid (AsA) can reduce DNA methylation in the locus and lead to an increase in gene expression in FX iPSCs and cerebral organoids. In addition, AsA treatment rescued neuronal gene expression and morphological defects observed in FX iPSC-derived cerebral organoids. Hence, we demonstrate that the dietary co-factor AsA can partially revert the molecular and morphological defects seen in human FX models in vitro. Our findings have implications for the development of novel therapies for FX in the future.

References

Esteban M, Wang T, Qin B, Yang J, Qin D, Cai J . Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. Cell Stem Cell. 2009; 6(1):71-9. DOI: 10.1016/j.stem.2009.12.001. View

Lancaster M, Knoblich J . Generation of cerebral organoids from human pluripotent stem cells. Nat Protoc. 2014; 9(10):2329-40. PMC: 4160653. DOI: 10.1038/nprot.2014.158. View

Pieretti M, Zhang F, Fu Y, Warren S, Oostra B, Caskey C . Absence of expression of the FMR-1 gene in fragile X syndrome. Cell. 1991; 66(4):817-22. DOI: 10.1016/0092-8674(91)90125-i. View

Sutcliffe J, Nelson D, Zhang F, Pieretti M, Caskey C, Saxe D . DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum Mol Genet. 1992; 1(6):397-400. DOI: 10.1093/hmg/1.6.397. View

Berry-Kravis E, Lindemann L, Jonch A, Apostol G, Bear M, Carpenter R . Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome. Nat Rev Drug Discov. 2017; 17(4):280-299. PMC: 6904225. DOI: 10.1038/nrd.2017.221. View

Yue X, Rao A . TET family dioxygenases and the TET activator vitamin C in immune responses and cancer. Blood. 2020; 136(12):1394-1401. PMC: 7498365. DOI: 10.1182/blood.2019004158. View

. Fmr1 knockout mice: a model to study fragile X mental retardation. The Dutch-Belgian Fragile X Consortium. Cell. 1994; 78(1):23-33. View

Kang Y, Zhou Y, Li Y, Han Y, Xu J, Niu W . A human forebrain organoid model of fragile X syndrome exhibits altered neurogenesis and highlights new treatment strategies. Nat Neurosci. 2021; 24(10):1377-1391. PMC: 8484073. DOI: 10.1038/s41593-021-00913-6. View

Kooy R, DHooge R, Reyniers E, Bakker C, Nagels G, De Boulle K . Transgenic mouse model for the fragile X syndrome. Am J Med Genet. 1996; 64(2):241-5. DOI: 10.1002/(SICI)1096-8628(19960809)64:2<241::AID-AJMG1>3.0.CO;2-X. View

10.

Stadtfeld M, Apostolou E, Ferrari F, Choi J, Walsh R, Chen T . Ascorbic acid prevents loss of Dlk1-Dio3 imprinting and facilitates generation of all-iPS cell mice from terminally differentiated B cells. Nat Genet. 2012; 44(4):398-405, S1-2. PMC: 3538378. DOI: 10.1038/ng.1110. View

11.

Hagerman R, Berry-Kravis E, Hazlett H, Bailey Jr D, Moine H, Kooy R . Fragile X syndrome. Nat Rev Dis Primers. 2017; 3:17065. DOI: 10.1038/nrdp.2017.65. View

12.

Park C, Halevy T, Lee D, Sung J, Lee J, Yanuka O . Reversion of FMR1 Methylation and Silencing by Editing the Triplet Repeats in Fragile X iPSC-Derived Neurons. Cell Rep. 2015; 13(2):234-41. DOI: 10.1016/j.celrep.2015.08.084. View

13.

Dahlhaus R . Of Men and Mice: Modeling the Fragile X Syndrome. Front Mol Neurosci. 2018; 11:41. PMC: 5862809. DOI: 10.3389/fnmol.2018.00041. View

14.

Wang T, Chen K, Zeng X, Yang J, Wu Y, Shi X . The histone demethylases Jhdm1a/1b enhance somatic cell reprogramming in a vitamin-C-dependent manner. Cell Stem Cell. 2011; 9(6):575-87. DOI: 10.1016/j.stem.2011.10.005. View

15.

Tsukada Y, Fang J, Erdjument-Bromage H, Warren M, Borchers C, Tempst P . Histone demethylation by a family of JmjC domain-containing proteins. Nature. 2005; 439(7078):811-6. DOI: 10.1038/nature04433. View

16.

Drozd M, Bardoni B, Capovilla M . Modeling Fragile X Syndrome in . Front Mol Neurosci. 2018; 11:124. PMC: 5911982. DOI: 10.3389/fnmol.2018.00124. View

17.

Willemsen R, Kooy R . Mouse models of fragile X-related disorders. Dis Model Mech. 2023; 16(2). PMC: 9903145. DOI: 10.1242/dmm.049485. View

18.

Urbach A, Bar-Nur O, Daley G, Benvenisty N . Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell. 2010; 6(5):407-11. PMC: 3354574. DOI: 10.1016/j.stem.2010.04.005. View

19.

Chiaradia I, Imaz-Rosshandler I, Nilges B, Boulanger J, Pellegrini L, Das R . Tissue morphology influences the temporal program of human brain organoid development. Cell Stem Cell. 2023; 30(10):1351-1367.e10. PMC: 10765088. DOI: 10.1016/j.stem.2023.09.003. View

20.

Eiges R, Urbach A, Malcov M, Frumkin T, Schwartz T, Amit A . Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos. Cell Stem Cell. 2008; 1(5):568-77. DOI: 10.1016/j.stem.2007.09.001. View